162 related articles for article (PubMed ID: 25826424)
1. Retinoids Bias Integrin Expression and Function in Cutaneous T-Cell Lymphoma.
Wang L; DeMarco SS; Chen J; Phillips CM; Bridges LC
J Invest Dermatol; 2015 Aug; 135(8):2102-2108. PubMed ID: 25826424
[TBL] [Abstract][Full Text] [Related]
2. RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.
Wang L; DeMarco SS; Peaks MS; Maiorana-Boutilier AL; Chen J; Crouch MJ; Shewchuk BM; Shaikh SR; Phillips CM; Bridges LC
Exp Dermatol; 2017 Nov; 26(11):1004-1011. PubMed ID: 28370539
[TBL] [Abstract][Full Text] [Related]
3. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
[TBL] [Abstract][Full Text] [Related]
5. About the cutaneous targets of bexarotene in CTCL patients.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
[TBL] [Abstract][Full Text] [Related]
6. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
7. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma.
Zhang C; Duvic M
Dermatol Ther; 2003; 16(4):322-30. PubMed ID: 14686975
[TBL] [Abstract][Full Text] [Related]
8. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
9. Integrins alpha4beta7 and alphaEbeta7 are expressed on epidermotropic T cells in cutaneous T cell lymphoma and spongiotic dermatitis.
Schechner JS; Edelson RL; McNiff JM; Heald PW; Pober JS
Lab Invest; 1999 May; 79(5):601-7. PubMed ID: 10334571
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids.
Stadler R; Kremer A
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S7-10. PubMed ID: 16516669
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cutaneous T-cell lymphoma with retinoids.
Zhang C; Duvic M
Dermatol Ther; 2006; 19(5):264-71. PubMed ID: 17014481
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
13. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.
Kempf W; Kettelhack N; Duvic M; Burg G
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1405-19. PubMed ID: 14710892
[TBL] [Abstract][Full Text] [Related]
14. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
[TBL] [Abstract][Full Text] [Related]
15. Effects of 9-cis-retinoic acid on the proliferation and apoptosis of cutaneous T-cell lymphoma cells.
Yang H; Tao Y; Zhang M; Ma P; Li L; Diao Q
Anticancer Drugs; 2019 Jan; 30(1):56-64. PubMed ID: 30198914
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
17. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand.
Braun FK; Al-Yacoub N; Plötz M; Möbs M; Sterry W; Eberle J
J Invest Dermatol; 2012 Feb; 132(2):429-39. PubMed ID: 22011910
[TBL] [Abstract][Full Text] [Related]
19. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL).
Burg G; Dummer R
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S41-4. PubMed ID: 11707863
[TBL] [Abstract][Full Text] [Related]
20. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]